Use of intravenous immunoglobulins (IVIGs) is a well-established therapy in patients with acute or chronic autoimmune thrombocytopenic purpura (ITP). The aim of the present open, prospective study was to investigate efficacy and safety of the novel IVIG preparation BT681 (Biotest Pharma GmbH, Dreieich, Germany) in adult patients with chronic ITP (cITP). In order to fulfil high standards of purity and viral safety, an additional HPLC step has been introduced and validated virus removal and inactivating procedures are included in the manufacturing process of BT681. A total of 24 patients with platelet counts between 3/nl and 27/nl received a total dose of 2 g/kg body weight BT681 in standard dosage regimens: 1.0 g/kg/day for 2 days in 15 patients and 0.4 g/kg/day for five consecutive days in nine patients. Platelet response (platelet count > or =50/nl) and regression of haemorrhages were documented during the 28 days study period and safety parameters including adverse events, laboratory investigations and vital signs were regularly monitored. The overall response rate was 91.7%, that is 22/24 patients responded to BT681 treatment. The median time to platelet response was 3.0 days, the duration of response 25.5 days; the median max. platelet count 222/nl and the time to max. platelet count 7.5 days. During the entire observation period, platelet counts below baseline were only observed in five responders; in half of the patients, platelet counts were even above 50/nl at the end of follow-up. Corresponding to the good platelet response, the clinical symptoms improved markedly in the majority of patients within the first week after start of BT681 infusions with 88.9% overall regression of haemorrhages in comparison with baseline. The evaluation of platelet parameters showed a slight tendency in favour of the 5 days group, evaluation of haemorrhage severity slight advantages for the 2 days group. The adverse event data indicate that the therapy with BT681 was safe and well tolerated in both treatment groups even if minor effects were more frequent in patients treated with the 2 days regimen. The large majority of adverse events were known intolerabilities during the treatment phase described as mild and transient. The results demonstrate that the new immunoglobulin preparation BT681 is effective and safe in the treatment of adult patients with cITP.
Monocytoid B cell lymphoma (MBCL) is an immunologically and morphologically well-defined low-grade lymphoma with a predilection for lymph nodes of the parotid region. We describe an association of MBCL with anti-myelin-associated glycoprotein (MAG) polyneuropathy in a 53-year-old male. The diagnosis of stage IV MBCL with nodular bone marrow infiltration, Sjögren’s syndrome and sensorimotor polyneuropathy was made in October 1996. Serum immunoelectrophoresis demonstrated IgMĸ paraprotein. This was then cross-reacted with epitopes of MAG and sulphated glucuronyl paragloboside (SGPG) on myelin sheaths, and detected by thin layer chromatography and Western blot. Direct immunofluorescence of a sural nerve biopsy showed loss of myelin fibres, segmental demyelinization and IgM deposits on the myelin sheaths. The cerebrospinal fluid was normal. After six cycles of chemotherapy (ChlVPP protocol), all the patient’s haematological parameters normalized accompanied by an improvement in neurological signs. The improvement of the polyneuropathy after chemotherapy indicates that the autoimmune anti-MAG and anti-SGPG antibodies resulted from the neoplastic lymphoid proliferation.
Prostatic adenocarcinoma rarely may involve the urinary bladder. Prostatic adenocarcinoma and high-grade transitional cell carcinoma (TCC) may coexist and account for the malignant cells seen in urinary cytology. Differentiating prostatic adenocarcinoma cells from those of TCC is important for therapy but remains difficult. A 10-year retrospective search identified 250 patients with high-grade carcinoma in urinary cytology. Among them, 6 cases of tissue-documented prostate adenocarcinoma were identified. The cytologic features of these cases were compared with those of 15 similarly documented cases of high-grade TCC. By using these criteria, 2 additional cases of prostatic adenocarcinoma were diagnosed prospectively. An oval nucleus with smooth borders; fine, powdery, evenly distributed nuclear chromatin and a large prominent nucleolus when present; and lack of significant pleomorphism are most helpful to differentiate prostatic adenocarcinoma from high-grade TCC. Recognizing these cells may be the first clue for the diagnosis of prostate adenocarcinoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.